| |

Discovering the Truth About Ketamine: A Conversation with Christi Myers of Flow Integrative

Discovering the Truth About Ketamine: A Conversation with Christi Myers of Flow Integrative
Discovering the Truth About Ketamine: A Conversation with Christi Myers of Flow Integrative

Now more than ever, society is seeking alternative therapies to help combat chronic conditions. The reliance on traditional pharmaceuticals as a “one-size fits all” solution leaves too many out of the equation.

Despite the incredible promise compounds like psilocybin, LSD, and ketamine have shown in fighting mental health issues like anxiety, depression, and PTSD, there are still those who doubt their efficacy. To these people, psychedelics are harmful substances shrouded in stigma.

Christi Myers and her team are here to shift that perception.

The founder and CEO of Flow Integrative, an integrative psychedelic wellness center offering ketamine therapies, Myers has had a lifelong passion for helping others. After coming of age in the family hospitality business, she turned her attention to the front lines at the age of 18 training as both an EMT and a firefighter.

She was first introduced to ketamine many years later when working as a paramedic and professor of Emergency Medical Services—something that changed the trajectory of her life forever.

“I was teaching emergency medicine, and that’s where ketamine found me,” Myers said in a conversation with Psychedelic Spotlight executive director, Swati Sharma. “Ketamine entered our drug box, and I found myself having to debunk my own belief system about what ketamine is and what it’s being used for.”

Myers educated herself on the compound, soon realizing it was not just another pharmaceutical or club drug, as it had been portrayed in the media.

“The more I dove into the medicine…the more I saw the potential for healing,” she revealed.

Since then, Myers has made it her mission to share her knowledge with the world—and help people heal in the process.

Ketamine’s Unique Chemistry Made it Ideal Treatment

Ketamine has catapulted into the public eye over the last several years. Evidence has shown the drug can be incredibly effective in helping those with depression, suicidal ideation, and PTSD. The FDA recently approved a ketamine-derivative nasal spray as a treatment for major depressive disorder.

Myers explains that ketamine works differently than traditional antidepressants because of its dissociative effects. The drug is able to switch off parts of our brains in order to reset, making it incredibly powerful for those with trauma. Understanding the science behind ketamine is something she insists will only seek to improve society’s understanding.

“Dissociating…allows the brain to cultivate new neural pathways that take us out of the default network, (and) put us into an expansive state of creating new neural pathways,” Myers explained. “And as we create new neural pathways…we’re able to modify our personality into a reality that is more in alignment with the life that we’ve created.”

Myers believes having a team of trained healthcare professionals with decades of experience is one of the best ways to promote healing while simultaneously breaking down stigmas.

Flow Integrative’s model is unique in that a member of their staff remains with you during the entire session, making sure no one is ever alone during their journey.

She noted that each practitioner at Flow Integrative has experienced the medicine, giving them a unique perspective and ability to support the patients.

“Ignorance is a choice…”

Despite a decades-long war on consciousness, where psychedelics were portrayed in a negative light, Myers maintains the time is now for people to discern fact from fiction. Where did these preconceived notions about ketamine and other compounds come from, and are they truly relevant?

“We must have the courage to ask ourselves, ‘is this opinion my truth? Or is this something that was just influenced by a story?’” she proclaimed. “Ignorance in this day and age is a choice.”

As more people face these tough questions, Myers continues to push for change. She continues to be an advocate for her patients and hopes her deep-rooted experience in the healthcare field will help push the narrative forward.

“That’s what I’ve been working toward, normalizing the word psychedelic,  exploring altered states of consciousness.”

 

 

If you’re ready to integrate ketamine therapy into your healing journey, contact Flow Integrative. Mention this article and receive $100 off one session.

 

Similar Posts

  • MindMed Nasdaq Uplisting STOCK PREDICTIONS // How Far will MindMed Go? [MMED/ MMEDF]

    Here are my MindMed NASDAQ uplisting STOCK PREDICTIONS! MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
    On the day the news was announced, MMED and MMEDF gained 65.26% , rising from $2.13 to a day high of to $3.57 Though in the last few days the price had fallen, it was still up by 30.86% over the past 2 weeks. MindMed volume increased on the last day, in total, 14 million more shares were traded that the day before. This giant bump brought a lot of MindMed stock speculation which is why we’re making this episode.

    Where does MindMed go from here on? MMED / MNMD is still just at the beginning of their long-term growth trajectory so we could only do our due diligence while speculating.
    Some speculate that some investors might feel inclined to take profits, which is absolutely understandable. But will they take profits right away or wait for the MNMD price to go ballistic or take profits right away? What will happen to the MindMed stock when/if the do?
    Others speculate that the uplisting event might create a FOMO movement which could more than 3X the stock’s price which could create a larger FOMO wave and bring MindMed’s stock price to a similar level to Compass Pathways who’s market cap is very close to MindMed’s.

    On this channel, we have been repeatedly saying that investing in the psychedelic industry and specifically in Mindmed should be a long-term play and that the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval. So….

    In this segment, we’ll discuss FOUR possible cases:
    Timestamps:
    0:00 – Intro
    4:17 – Worst Case
    7:48 – Probable Case
    9:57 – #WINNING CASE
    11:58 – APES TOGETHER STRONG CASE

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MindMedNasdaq #MindMedstock

  • The Psychedelic Sector has Reached “Escape Velocity” | An interview with Cybin’s CEO (CYBN)

    In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.

    In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?

    The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?

    Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.

    Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.

    It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.

    James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.

    In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.

    Enjoy the episode!

    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy
    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Cybin #Psilocybin #Psychedelics